UK Cardiac Resynchronization Therapy Market

UK Cardiac Resynchronization Therapy Market Executive Summary

UK Cardiac Resynchronization Therapy Market valued at $125 Mn in 2022, projected to reach $158 Mn by 2030 with a 3% CAGR.

Cardiac resynchronization therapy (CRT) is a medical procedure that involves the use of a pacemaker to correct the heart's rhythm through a minor surgical intervention. The CRT pacemaker, implanted beneath the skin, coordinates the timing between the upper and lower heart chambers and synchronizes the left and right sides of the heart. This therapy is particularly important for individuals with heart failure, as it helps to address inadequate pumping and fluid accumulation in the lungs and legs due to the asynchronous beating of the heart's lower chambers. In some cases of severe heart rhythm issues, an implantable cardioverter-defibrillator (ICD) may be combined with CRT therapy. The CRT device connects wires from the pacemaker to both sides of the heart, employing biventricular pacing to ensure coordinated contractions and optimize overall heart function.

The UK has witnessed a concerning increase in heart attacks and cardiovascular-related deaths since 2023, with over 500 people per week succumbing to these conditions. Ischaemic heart disease became the leading cause of death, with England and Wales reporting 77.0 and 85.8 deaths per 100,000 people, respectively. Despite a decline in age-standardized death rates, the recent surge in cardiovascular-related deaths is alarming, necessitating comprehensive investigations and coordinated efforts from public health authorities to address the escalating crisis.

Medtronic and US-based Iceni Diagnostics are collaborating on a study using a drug-eluting lead to reduce inflammation around implant sites, potentially extending pacemaker lifespan and improving patient outcomes. Meanwhile, St. Jude Medical, now part of Abbott, has gained UK approval for their innovative drug-eluting lead using dexamethasone to prevent scar tissue formation. This represents a significant advancement in cardiac implant technology, aiming to enhance pacemaker longevity and reduce complications, showcasing Abbott's commitment to medical innovation and patient care.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Cardiovascular Disease (CVD): The UK has witnessed a significant surge in the number of excess fatalities linked to cardiovascular issues, with more than 500 individuals per week falling victim to heart attacks or strokes. CVD stands as the primary contributor to mortality in the country, and ailments such as heart failure, a primary focus for CRT, are experiencing a rise in prevalence. This expanding patient demographic is driving the need for CRT interventions.

Aging Population: In 2023, more than 11 Mn individuals in the UK are 65 years old or above, constituting 19% of the overall population. Projections indicate a continuous increase in this demographic, with expectations that it will reach 22% by 2033. The aging population in the UK is associated with an elevated risk of cardiovascular diseases (CVD) due to the correlation between age and CVD. This demographic transition serves to amplify the market potential for Cardiac Resynchronization Therapy (CRT).

Technological Advancements in CRT: Recent technological advancements in CRT devices have significantly transformed the landscape of heart failure treatment. The latest generation of CRT devices is distinguished by its compact design, enhanced energy efficiency, and sophisticated functionalities including wireless connectivity and remote monitoring. These improvements lead to better treatment outcomes in addition to increased patient comfort. The use of CRT therapy is being fuelled by its greater accessibility and appeal to patients and healthcare professionals.

Market Restraints

Competition from Alternative Therapies: In addition to high costs and regulatory challenges, CRT faces competition from alternative therapies. Medications, lifestyle changes, His bundle pacing (HBP), left bundle branch area pacing (LBBAP), and leadless left ventricular (LV) pacing emerge as less expensive and invasive alternatives to CRT. While these alternatives may not directly replace CRT, they influence physician treatment decisions, particularly in specific patient segments. This competition introduces a dynamic element to the landscape, prompting healthcare professionals to carefully consider the most suitable and cost-effective treatment options for their patients.

Stringent Regulatory Landscape: The introduction of new and innovative CRT technologies in the Spanish market is impeded by a stringent regulatory landscape governing medical device approval. Manufacturers face significant delays and increased costs while navigating these regulations, hindering the timely availability of CRT advancements. This regulatory burden poses a considerable challenge to market growth, as compliance becomes a time-consuming and costly aspect for manufacturers seeking to bring their products to the market.

High Device Cost: Cardiac Resynchronization Therapy (CRT) devices come with a substantial financial burden, as their prices vary based on the brand and features. The cost is further escalated for MRI-compatible versions. The potential deterrents include limited insurance coverage and high out-of-pocket expenses, discouraging both patients and healthcare providers from choosing CRT therapy. In developing countries, the absence of government-imposed price caps on these devices exacerbates the financial barrier, limiting access to this advanced medical technology.

Healthcare Policies and Regulatory Landscape

In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA), functioning as an executive agency within the Department of Health and Social Care, primarily oversees healthcare policies and regulatory processes related to treatment drugs. The MHRA plays a crucial role in ensuring the safety, effectiveness, and quality of medicines by overseeing activities such as granting marketing authorization, approving clinical trials, and conducting continuous pharmacovigilance. Moreover, the National Institute for Health and Care Excellence (NICE) contributes by guiding the clinical and cost-effectiveness of treatments, influencing the pricing and reimbursement structures for drugs. The dynamic interaction between these regulatory bodies significantly influences the landscape governing the development, approval, and accessibility of treatment drugs in the UK.

Competitive Landscape

Key Players

• Abbott
• Boston Scientific
• Biotronik
• Medtronic
• St. Jude Medical
• Sorin Group
• LivaNova
• MicroPort Aps
• Osypka Med
• Terumo Corporation